Zenas BioPharma (ZBIO) Expected to Announce Earnings on Wednesday

Zenas BioPharma (NASDAQ:ZBIO) will likely be posting its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect Zenas BioPharma to post earnings of ($1.22) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 9:30 AM ET.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Zenas BioPharma Trading Up 3.8%

ZBIO stock opened at $21.80 on Monday. Zenas BioPharma has a one year low of $6.11 and a one year high of $44.60. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -3.08 and a beta of -1.47. The company has a fifty day moving average price of $28.88 and a two-hundred day moving average price of $25.44. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66.

Insider Transactions at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. bought 57,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was bought at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the transaction, the chief executive officer owned 423,155 shares of the company’s stock, valued at $7,599,863.80. This represents a 15.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought 157,000 shares of company stock worth $2,662,720 in the last 90 days. Corporate insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in Zenas BioPharma by 17.2% in the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after buying an additional 170,546 shares during the period. Geode Capital Management LLC raised its position in shares of Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after acquiring an additional 16,461 shares in the last quarter. Invesco Ltd. acquired a new position in shares of Zenas BioPharma in the 3rd quarter valued at about $3,237,000. Millennium Management LLC bought a new stake in shares of Zenas BioPharma during the 3rd quarter valued at about $1,595,000. Finally, UBS Group AG grew its stake in Zenas BioPharma by 46.3% during the third quarter. UBS Group AG now owns 35,492 shares of the company’s stock worth $788,000 after purchasing an additional 11,229 shares during the period.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Evercore started coverage on shares of Zenas BioPharma in a research report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price objective for the company. HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Jefferies Financial Group reissued a “buy” rating and set a $48.00 target price on shares of Zenas BioPharma in a report on Tuesday, January 6th. Finally, Wall Street Zen cut shares of Zenas BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.14.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.